An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
This study is being conducted to explore the efficacy of SHR-6390 and SHR-1020 in the treatment of esophageal squamous cell carcinoma after progression on PD-1 Antibody.
Esophageal Squamous Cell Carcinoma|Progression to PD-1 Antibody
DRUG: SHR-6390|DRUG: SHR-6390 + Camrelizumab (SHR-1210)|DRUG: Camrelizumab (SHR-1210) + SHR-1020
Objective Response Rate, Objective Response Rate is defined as the percentage of patients whose tumors have a complete or partial response to treatment among eligible and treated patients. Objective response rate is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1 criteria., 1 year
Progression-Free-Survival, Progression-Free-Survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first., Up to 1 year|Overall survival, Overall survival is defined as time from treatment start date to date of death from any cause. Patients alive at the time of analysis are censored at last contact date., Up to 1 year|Subject safety, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0., Up to 1 year
This study is being conducted to explore the efficacy of SHR-6390 and SHR-1020 in the treatment of esophageal squamous cell carcinoma after progression on PD-1 Antibody.